Pfizer Limited (BOM:500680)

Market Cap	185.74B -21.0%
Revenue (ttm)	25.70B +10.7%
Net Income	7.35B -9.1%
EPS	160.70 -9.1%
Shares Out	n/a
PE Ratio	25.27
Forward PE	22.09
Dividend	75.00 (1.83%)
Ex-Dividend Date	Jul 17, 2026

Volume	5,407
Open	4,095.00
Previous Close	4,096.25
Day's Range	4,054.55 - 4,115.15
52-Week Range	4,054.55 - 5,561.55
Beta	n/a
Analysts	Buy
Price Target	6,008.50 (+47.92%)
Earnings Date	Nov 12, 2026

About Pfizer

Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterology, pain management, and nutrition, addressing. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products t...

• Industry: Pharmaceutical Preparations
• Founded: 1950
• Employees: 1,244
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 500680

Financial Performance

In fiscal year 2026, Pfizer's revenue was 25.20 billion, an increase of 10.45% compared to the previous year's 22.81 billion. Earnings were 7.22 billion, a decrease of -5.88%.

Analyst Summary

According to 4 analysts, the average rating for 500680 stock is "Buy." The 12-month stock price target is ₹6,009, which is an increase of 47.92% from the latest price.

Price Target

₹6,009

(47.92% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 14, 2026

Data Sources Report a data error